Publications by authors named "S Ruetz"

Claim this Profile
D
Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors.
Anselm F L Schneider, Joerg Kallen, Johannes Ottl, Patrick C Reid, Sebastien Ripoche, Stephan Ruetz

RSC Chem Biol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A Chapeau, Stephan Ruetz

Cancer Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.
Andrea Vaupel, Philipp Holzer, Stephane Ferretti, Vito Guagnano, Joerg Kallen, Stephan Ruetz

Bioorg Med Chem Lett· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical assessment of the synthesis and biological activity of p53/human double minute 2-stapled peptide inhibitors.
Rike Wallbrecher, Patrick Chène, Stephan Ruetz, Therese Stachyra, Thomas Vorherr

Br J Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Stephan Ruetz

Elife· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis